国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01099 国药控股

午间休市 11-10 12:05:00

17.130

-0.020

-0.12%

最高17.260	最低17.010	成交量130.79万
今开17.050	昨收17.150	日振幅1.46%
总市值534.63亿	流通市值229.85亿	总股本31.21亿
成交额2,243万	换手率0.10%	流通股本13.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":17.13,"timestamp":1794283500002,"preClose":17.15,"halted":0,"volume":1307889,"delay":0,"changeRate":-0.001166180758017468,"floatShares":1341810740,"shares":3121000000,"eps":2.693320026978699,"marketStatus":"午间休市","change":-0.02,"latestTime":"11-10 12:05:00","open":17.05,"high":17.26,"low":17.01,"amount":22431247,"amplitude":0.014577,"askPrice":17.14,"askSize":10000,"bidPrice":17.13,"bidSize":5600,"shortable":3,"etf":0,"ttmEps":2.6934952691987952,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794286800000},"marketStatusCode":3,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":17.15,"dividendRate":0.046083,"openAndCloseTimeList":[[1794274200000,1794283200000],[1794286800000,1794297600000]],"volumeRatio":0.42822,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.2152,"impliedVolPercentile":0.0528},"requestUrl":"/m/hq/s/01099","defaultTab":"news","newsList":[{"id":"2682386166","title":"国药控股：与中国医药集团签订二零二六年框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2682386166","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682386166?lang=zh_cn&edition=full","pubTime":"2026-11-09 21:28","pubTimestamp":1794230882,"startTime":"0","endTime":"0","summary":"21财经11月9日电，国药控股（01099.HK）公告，公司于2026年11月9日与中国医药集团（简称“国药集团”）签订《二零二六年采购框架协议》《二零二六年销售框架协议》《二零二六年金融服务框架协议》《二零二六年EPC总承包服务框架协议》及《二零二六年保理服务框架协议》，协议有效期自2027年1月1日起至2029年12月31日止，为期三年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611093926518481.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611093926518481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0010","01099","BK0185","BK0250","BK0028","BK1197","BK1500","LU1115378108.SGD","03069","600056","BK0082","LU0640798160.USD","BK1610","BK1515","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166544271","title":"国药控股拟续签五项框架协议　2027-2029年采购年上限72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166544271","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166544271?lang=zh_cn&edition=full","pubTime":"2026-11-09 21:20","pubTimestamp":1794230448,"startTime":"0","endTime":"0","summary":"国药控股11月9日公告，公司已与控股股东中国医药集团有限公司及其附属公司续签五项框架协议，涵盖采购、销售、EPC 总承包服务、保理服务及金融服务，协议期限均为2027年1月1日至2029年12月31日，合计三年。其中，采购框架协议和金融服务框架协议须获独立股东批准后方可生效。国药集团及其联繫人将就相关决议案回避表决。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123362980","title":"国药控股：摩根大通减持，好仓比例降至4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123362980","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123362980?lang=zh_cn&edition=full","pubTime":"2026-11-09 17:33","pubTimestamp":1794216827,"startTime":"0","endTime":"0","summary":"摩根大通于2026年11月4日以每股均价16.7096港元场外卖出国药控股（01099）股份57.97万股，涉资约968.68万港元，持股量降至5%以下。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次减持前持有国药控股好仓6747.44万，占比5.02%；减持后持股量为6689.46万，好仓比例降至4.98%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682806370","title":"摩根大通在国药控股的H股好仓比例下降0.04%至4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682806370","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682806370?lang=zh_cn&edition=full","pubTime":"2026-11-09 17:27","pubTimestamp":1794216476,"startTime":"0","endTime":"0","summary":"21财经11月9日电，香港交易所披露信息显示，JPMorganChase&Co.（摩根大通）在国药控股的H股好仓（L）比例于11月4日从5.02%下降至4.98%。同时淡仓（S）比例从0.87%降至0.86%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611093926330575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611093926330575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01099","LU1115378108.SGD","BK1500","PGF","LU0640798160.USD","BK1515","BK4582","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159360377","title":"国药控股：摩根大通增持，好仓比例升至5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159360377","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159360377?lang=zh_cn&edition=full","pubTime":"2026-11-09 17:14","pubTimestamp":1794215670,"startTime":"0","endTime":"0","summary":"摩根大通于2026年11月3日通过取得股份的保证权益，以每股均价16.6783港元，场外增持国药控股（01099）H股47.71万股，涉资约795.73万港元，属场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次增持前持有国药控股好仓6699.73万股，占比4.99%；增持后持股量为6747.44万股，好仓比例升至5.02%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681762851","title":"摩根大通在国药控股的H股好仓比例下降0.05%至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681762851","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681762851?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:21","pubTimestamp":1793956860,"startTime":"0","endTime":"0","summary":"南财智讯11月6日电，香港交易所披露信息显示，JPMorganChase&Co.（摩根大通）在国药控股的H股好仓（L）比例于11月2日从5.04%下降至4.99%。同时淡仓（S）比例从0.88%降至0.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611063924906393.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611063924906393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0640798160.USD","PGF","BK1515","01099","BK1500","BK1197","LU1115378108.SGD","BK4582"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118371935","title":"国药控股：摩根大通减持，好仓比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118371935","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118371935?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:16","pubTimestamp":1793956565,"startTime":"0","endTime":"0","summary":"摩根大通于2026年11月2日以每股均价16.3551港元，场外卖出国药控股（01099）股份70.91万股（代价性质：现金），涉资约1159.70万港元；该笔为场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次减持前持有国药控股好仓6770.63万，占比5.04%；减持后持股量为6699.73万，好仓比例降至4.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681002953","title":"Lazard Asset Management LLC增持国药控股(01099)约539.77万股 每股作价16.19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681002953","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681002953?lang=zh_cn&edition=full","pubTime":"2026-11-05 19:28","pubTimestamp":1793878112,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月30日，Lazard Asset Management LLC增持国药控股(01099)539.7677万股，每股作价16.19港元，总金额约为8738.84万港元。增持后最新持股数目约为1.91亿股，最新持股比例为14.26%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0640798160.USD","LU1115378108.SGD","BK1515","EWH","01099","BK1500","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160784205","title":"国药控股：Lazard Asset Management LLC增持，好仓比例升至14.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160784205","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160784205?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:15","pubTimestamp":1793870109,"startTime":"0","endTime":"0","summary":"Lazard Asset Management LLC于2026年10月30日在联交所场内以每股均价16.19港元买入国药控股（01099）股份539.77万股，涉资约8738.84万港元，属场内主动交易，即在二级市场直接买卖股份。Lazard Asset Management LLC此次增持前持有国药控股好仓1.86亿，占比13.86%；增持后持股量为1.91亿，好仓比例升至14.26%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198565067","title":"国药控股10月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1198565067","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198565067?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:36","pubTimestamp":1793867795,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司（01099）于2026年11月5日发布了截至2026年10月31日的月报表。公告显示，本月公司股本结构保持稳定，未发生任何新增发行、购回、注销或库藏股活动。\n根据公告，截至报告期末，公司注册股本总额维持在人民币3,120,656,191元，已发行及未包含在库藏股份中的股份数量为H股1,341,810,740股，内资股1,778,845,451股，均较上月底无增减变动。报告期内未有任何股份期权计划、股权激励计划及购回注销等其他股份变动事项。\n公司确认目前满足香港联交所《上市规则》关于最低公众持股量的相关规定。本次公告由公司秘书吴壹建签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680303066","title":"摩根大通增持国药控股(01099)约115.50万股 每股作价约16.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680303066","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680303066?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:22","pubTimestamp":1793791355,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月30日，摩根大通增持国药控股(01099)115.5044万股，每股作价16.1441港元，总金额约为1864.71万港元。增持后最新持股数目约为6770.63万股，最新持股比例为5.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PGF","LU1115378108.SGD","BK1500","BK1515","BK4582","BK1197","EWH","LU0640798160.USD","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680397340","title":"摩根大通在国药控股的H股好仓比例上升0.09%至5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680397340","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680397340?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:22","pubTimestamp":1793784159,"startTime":"0","endTime":"0","summary":"南财智讯11月4日电，香港交易所披露信息显示，JPMorganChase&Co.（摩根大通）在国药控股的H股好仓（L）比例于10月30日从4.95%上升至5.04%。同时淡仓（S）比例从0.83%升至0.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611043922031459.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611043922031459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1197","LU1115378108.SGD","PGF","BK1500","BK4582","LU0640798160.USD","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141846731","title":"国药控股：摩根大通增持，好仓比例升至5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141846731","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141846731?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:11","pubTimestamp":1793783476,"startTime":"0","endTime":"0","summary":"摩根大通于2026年10月30日以每股均价16.1441港元场外买入国药控股（01099）股份115.50万股，涉资约1864.71万港元。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次增持前持有国药控股好仓6655.13万，占比4.95%；增持后持股量为6770.63万，好仓比例升至5.04%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130436344","title":"国药控股：摩根大通减持，好仓比例降至4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130436344","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130436344?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:23","pubTimestamp":1793697813,"startTime":"0","endTime":"0","summary":"摩根大通于2026年10月28日以每股均价15.9148港元场外减持国药控股（01099）129.06万股，涉资约2054.01万港元；该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖，交易后其持股量降至5%以下。摩根大通此次减持前持有国药控股好仓6817.89万，占比5.08%；减持后持股量为6688.82万，好仓比例降至4.98%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786312","title":"【券商聚焦】中信建投：中国医药资产全球性价比凸显，内外协同空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786312?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:46","pubTimestamp":1793580413,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报称，2026年欧洲内科肿瘤学会 中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。该机构指，中国医药具有“创新升级+供应链韧性”优势，2025年创新药海外授权首付款大幅超去年全年，器械也在积极探索出海路径。美国主导早期研发与高端定价，但跨国药企专利悬崖下需求旺盛，中国资产全球性价比凸显，内外协同空间广阔。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","LU2476274308.USD","LU1969619763.USD","BK1515","LU0540923850.HKD","SG9999004311.SGD","601066","IE00B5MMRT66.SGD","BK0188","03069","LU2476274720.SGD","01530","LU2399975544.HKD","03933","09926","01789","LU0634319403.HKD","BK1610","LU0228659784.USD","LU0348825331.USD","LU0588546209.SGD","01099","BK1617","600056","BK1161","LU0348783233.USD","LU0348767384.USD","09688","LU0417516902.SGD","LU0348766576.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU0307460666.USD","02367","LU1251922891.USD","KCE","LU2488822045.USD","SG9999014674.SGD","BK0028","02268","KURE","02196","06821","LU1720050803.USD","02228","BK1141","LU0561508036.HKD","06160","BK1207","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112352233","title":"国药控股(01099)披露子公司国药一致2026年三季报：单季营收188.00亿元净利增18.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112352233","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112352233?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:45","pubTimestamp":1793360751,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司10月30日公告，其控股子公司国药集团一致药业股份有限公司公布2026年第三季度主要未经审计财务数据。本报告期，国药一致实现营业收入188.00亿元，同比增长2.57%；归属于上市公司股东的净利润为3.46亿元，同比增长18.91%；扣除非经常性损益后归属于上市公司股东的净利润为3.46亿元，同比增长23.47%。截至2026年9月30日，国药一致总资产为489.04亿元，较上年末下降0.39%；归属于上市公司股东的所有者权益为192.20亿元，较上年末增长3.28%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192893065","title":"国药控股(01099)：附属公司国药一致2026年前三季度收入550.66亿元 第三季度净利同比增18.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192893065","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192893065?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:41","pubTimestamp":1793360494,"startTime":"0","endTime":"0","summary":"2026年10月30日，国药控股发布海外监管公告，披露其深圳上市附属公司国药集团一致药业股份有限公司2026年第三季度报告。2026年前三季度，国药一致实现营业收入550.66亿元，同比下降0.11%；归属于上市公司股东的净利润为9.52亿元，同比下降0.48%。截至2026年9月30日，国药一致总资产为489.04亿元，较年初下降0.39%；归属于上市公司股东的所有者权益为192.20亿元，较年初增加3.28%。根据公告，医药分销收入降幅已收窄，零售业务盈利能力有所改善。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678439694","title":"中金：维持国药控股(01099)“跑赢行业”评级 目标价21.25港元 1-3Q26业绩符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2678439694","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678439694?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:58","pubTimestamp":1793156305,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，国药控股2026年前三季度实现营业收入4,276.13亿元，同比下降0.90%；归母净利润53.14亿元，同比增长0.13%，业绩符合该行预期。国大药房前三季度净利润同比大幅增长零售板块方面，2026年前三季度，子公司国大药房实现营业收入152.34亿元，同比增长0.05%；实现净利润0.27亿元，同比增长105.08%。2026年第三季度，公司毛利率为7.5%，同比持平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678172253","title":"国药控股：与国药数科签订二零二六年信息技术服务框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2678172253","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678172253?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:58","pubTimestamp":1793102280,"startTime":"0","endTime":"0","summary":"南财智讯10月27日电，国药控股（01099.HK）公告，2026年10月27日，公司与国药数科签订二零二六年信息技术服务框架协议，协议期限为三年。根据协议，本集团将向国药数科采购云网基础设施及模型算力服务，以及其他各类信息技术服务，包括技术服务、技术开发、软件开发、信息系统集成服务及大数据服务等。该交易构成公司的持续关连交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610273910294245.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610273910294245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARKG","VGT","LU0640798160.USD","LU1115378108.SGD","BK1515","BK4588","BK4585","01099","BK1500","BK4544","159939","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135232843","title":"国药控股(01099)签订三年期信息技术服务框架协议 最高年度上限1.73亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135232843","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135232843?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:56","pubTimestamp":1793102201,"startTime":"0","endTime":"0","summary":"2026年10月27日，国药控股股份有限公司公告称，公司已与国药数字科技（北京）有限公司签订《二零二六年信息技术服务框架协议》，协议期限自2026年10月27日起至2029年10月26日止，共计三年。双方约定，交易须按照不逊于独立第三方的公平商业条款进行，且国药控股保留向第三方采购同类服务的权利。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":0.0496},{"period":"1month","weight":0.1533},{"period":"3month","weight":0.019},{"period":"6month","weight":-0.0146},{"period":"1year","weight":-0.097},{"period":"ytd","weight":-0.0729}],"compareEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0735},{"period":"1year","weight":-0.0683},{"period":"ytd","weight":-0.0461}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品、医疗保健产品及医疗器械批发和零售业务的中国公司。该公司通过四个部门运营业务。医药分销部门为国内外药品及保健品制造商及其他供货商提供分销、物流及其他加值服务。器械分销部门向客户分销医疗器材。医药零售业务部门拥有直接经营或特许经营的零售药局网路。其他业务部门从事药品、化学试剂及实验室用品的制造与销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004652},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029404},{"month":3,"riseRate":0.470588,"avgChangeRate":0.00701},{"month":4,"riseRate":0.411765,"avgChangeRate":0.016475},{"month":5,"riseRate":0.588235,"avgChangeRate":-0.009205},{"month":6,"riseRate":0.411765,"avgChangeRate":-0.006214},{"month":7,"riseRate":0.529412,"avgChangeRate":-0.008781},{"month":8,"riseRate":0.411765,"avgChangeRate":0.005041},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.012951},{"month":10,"riseRate":0.666667,"avgChangeRate":0.044905},{"month":11,"riseRate":0.5,"avgChangeRate":-0.003591},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004119}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}